Filing summary
Entity mismatch: The supplied filing is Synta Pharmaceuticals Corp.’s Form 10-Q, not a filing for Madrigal Pharmaceuticals, Inc. The summary below reflects Synta’s filing for the quarter ended March 31, 2015.
Business context and reporting period
Synta was a clinical-stage oncology biopharmaceutical company with no product revenue. Its programs included ganetespib, elesclomol, and its Hsp90 drug-conjugate platform, including lead candidate STA-12-8666. The unaudited financial statements cover the three months ended March 31, 2015, with comparison to the same period in 2014.
Financial performance and liquidity
- Revenue was zero in both quarters. Research and development expense was $16.2 million, down 8% from $17.6 million; general and administrative expense was $4.2 million, down 23% from $5.3 million.
- Operating loss was $20.3 million versus $22.9 million; net loss was $20.7 million, or $0.19 per share, versus $23.6 million, or $0.28 per share. Lower expenses and interest costs contributed to the narrower loss; weighted-average shares increased to 108.4 million from 85.4 million.
- Operating cash use was $18.8 million versus $20.3 million. Cash, cash equivalents, and marketable securities totaled $76.6 million at quarter-end, down from $97.7 million at December 31, 2014. Working capital was $47.1 million.
- Total term-loan principal was approximately $11.5 million, including $9.2 million current and $2.3 million long-term. The GECC loan carried 9.75% interest and the remaining Oxford equipment loan 13.35%; debt principal payments were $2.3 million during the quarter. The loans are secured and include restrictive covenants.
- In April 2015, Synta raised approximately $41.8 million net from a public offering. Management said quarter-end resources plus offering proceeds were expected to fund operations at least through the first half of 2016, assuming no additional financing or partnership proceeds.
Material developments, outlook, and risks
- Ganetespib’s Phase 3 GALAXY-2 trial had enrolled more than 500 patients; the first interim overall-survival analysis was expected in the second half of 2015. Synta anticipated later interim and final analyses in 2016 and planned to seek approval in 2016 only if results were positive and subject to regulatory feedback.
- GALAXY-1 results in the subgroup enrolled more than six months after diagnosis showed median overall survival of 11.0 months with ganetespib plus docetaxel versus 7.4 months with docetaxel, and median progression-free survival of 5.3 versus 3.4 months. These Phase 2 subgroup findings do not establish Phase 3 success; other analyzed populations showed mixed results.
- STA-12-8666 entered IND-enabling studies, with an IND submission targeted for the first quarter of 2016. Research and development spending could rise as the company advanced this candidate and conducted late-stage ganetespib trials.
- Management warned that the company expected significant future losses and cash use, had no product revenue, and might need additional funding earlier than expected. Financing may be unavailable or dilutive, and partnership arrangements could require surrendering rights. Clinical, regulatory, and commercialization outcomes remain uncertain.
- CEO Anne Whitaker announced her resignation effective May 7, 2015; COO Chen Schor was appointed President and CEO effective that date. Synta reported no material legal proceedings and no material changes to its previously disclosed risk factors.
Important facts for investors to verify
- Confirm the intended company: this filing is for Synta, not Madrigal Pharmaceuticals.
- Check subsequent GALAXY-2 trial updates and whether the projected analyses and regulatory plans occurred.
- Assess cash burn, financing needs, dilution, and the assumptions behind the stated runway, including the April offering proceeds.
- Review loan repayment schedules, collateral, covenants, and any subsequent amendments or defaults.
- Verify subsequent development progress for STA-12-8666 and other clinical programs, as well as the effects of the CEO transition.